Clinical Trial Detail

NCT ID NCT02648477
Title Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors City of Hope Medical Center
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Bevacizumab

Letrozole

Anastrozole

Exemestane

Doxorubicin

Age Groups: adult

Additional content available in CKB BOOST